Navigation Links
Amorcyte Stem Cell Therapy Demonstrates Clinically Significant Reperfusion in Severe Heart Attack Patients
Date:12/21/2010

ALLENDALE, N.J., Dec. 21, 2010 /PRNewswire/ -- The American Heart Journal today reported results of a clinical trial evaluating Amorcyte, Inc.'s lead product candidate, AMR-001 for the treatment of damaged heart muscle following acute myocardial infarction (AMI).  Data demonstrated a significant relationship between cell dose and biologic effect. This is the first and only study to prospectively define a dose of a purified and potent autologous (self-donating) stem cell therapy that resulted in a significant improvement in perfusion, a trend towards improved cardiac function and the potential to reduce subsequent adverse cardiac events following AMI.

The report was authored by researchers from Emory University, Northwestern University, Texas Heart Institute, The Christ Hospital Heart and Vascular Center in Cincinnati, Ohio, Mayo Clinic College of Medicine, Amorcyte, Inc. and Progenitor Cell Therapy, LLC.

The 31 patients in the Phase I trial were randomly assigned to an autologous stem cell harvest group (cells were harvested from the patient's own bone marrow) or control group five days after an ST elevation myocardial infarction (STEMI) characterized by a prolonged period of hypoperfusion (blocked blood supply).  CD34+ cells having CXCR-4+ receptors were then isolated from the bone marrow, and enriched to increase potency using Amorcyte's patented technology into five, 10 and 15 million cell doses.  The cells were infused into the patient via the infarct-related artery seven to 11 days following the STEMI – the optimal time frame to attempt to prevent adverse ventricular remodeling.  Caused by the progressive decline in heart muscle function following an AMI, ventricular remodeling can lead to permanent heart damage and increase the risk of recurrent heart attack, other adverse cardiac events and death. 

The study results demonstrated that patients receiving 10 to 15 million cells (n=9) experienced sig
'/>"/>

SOURCE Amorcyte, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Advanced Laser Therapy Solutions for Womens Hair Loss
2. Physiotherapy Associates Announces New Multiple Sclerosis Specialty Treatment Program
3. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
4. New York Robotic Surgery Expert Dr. David Samadi, MD Discusses New Findings that Hormone Therapy May Increase Risk of Developing Colorectal Cancer
5. Passages Malibu Drug and Alcohol Treatment Center Announces Launch of Cutting-Edge Brain Paint Neurofeedback Therapy Scientifically Proven to Reduce Addiction Relapse Rate Into Pioneering Holistic Treatment Program
6. Elekta Receives FDA 510(k) Clearance for XiO Software to Plan Spot Scanning for Proton Therapy
7. Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinsons Disease
8. VeriStrat® Test Identifies Lung Cancer Patients Benefiting from Combination Therapy
9. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
10. Exempla Saint Joseph Hospital Commences Treating Cancer Patients Using New TrueBeam™ System for High-Precision Image-Guided Radiotherapy and Radiosurgery
11. NT-proBNP Guided Therapy Keeps Heart Failure Patients out of the Hospital Through a Reduction in Cardiovascular Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... , May 6, 2015  Rigrodsky & Long, P.A.: ... Inc. (NASDAQ GM: AERI )? , Did you purchase ... , Did you lose money in your investment in Aerie ... Rigrodsky & Long, P.A. , including ... announces that a complaint has been filed in the United States ...
(Date:5/6/2015)... South Africa , May 6, 2015 ... than HIV/AIDS, malaria and tuberculosis combined[1]. Approximately 40 percent of ... cured with the right treatment[3]. Together with Elekta, ministries of ... build up their radiation therapy infrastructures and save lives. ... would benefit from radiation therapy[4] during the course of their ...
(Date:5/6/2015)... Markets ( http://www.researchandmarkets.com/research/jskhnb/energy_based ) has announced the addition ... Business Report" report to their offering. The ... Canada , Japan , ... of World. Annual estimates and forecasts are provided for the ... provided for these markets. The global market is ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aerie Pharmaceuticals, Inc. 2SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aerie Pharmaceuticals, Inc. 3Elekta to bring cancer treatment to millions in Africa 2Elekta to bring cancer treatment to millions in Africa 3Elekta to bring cancer treatment to millions in Africa 4Energy based Ablation Devices - Global Strategic Business Report 2015: Increasing Incidence of Cancer Bodes Well For Energy Based Ablation Devices 2Energy based Ablation Devices - Global Strategic Business Report 2015: Increasing Incidence of Cancer Bodes Well For Energy Based Ablation Devices 3
(Date:5/6/2015)... Chesapeake Regional Medical Center is the ... acquire Intuitive Surgical, Inc.’s latest model of the ... enhanced surgical technique capabilities, which can be used ... spectrum of specialties. Its advancements allow patients less ... times. , “As the only independent, community-based hospital ...
(Date:5/6/2015)... May 06, 2015 The Beryl Institute ... of Patient Experience Journal (PXJ), an international, open ... around understanding and improving patient experience. The second volume ... experience conversation globally, helps align the voices engaged and ... , Published in association with The Beryl Institute, Volume ...
(Date:5/6/2015)... 06, 2015 Is Colorado’s legal cannabis ... month the Centennial State will mark the 18-month milestone ... to adults. And while Colorado’s legal marijuana industry has ... time, it’s also facing some new challenges. , For ... facing shortages, especially in the wake of last month’s ...
(Date:5/6/2015)... vcfo, a specialized consulting firm that provides ... to optimize business performance and productivity, announced the additions ... Scheaffer. Both Lynch and Scheaffer have more than 25 ... “We are delighted to add Jack and Mike to ... background in financial management and leadership, Mike and Jack ...
(Date:5/6/2015)... Anitoa Systems, (“Anitoa”), a Palo Alto startup ... China, has successfully demonstrated a handheld real time quantitative-polymerase-chain-reaction ... Anitoa’s handheld qPCR is shown to be capable of ... hepatitis B, C, and E. Coli. This qPCR system ... and over 9 orders of magnitude dynamic range. ...
Breaking Medicine News(10 mins):Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 3Health News:Patient Experience Journal Releases Spring 2015 Issue 2Health News:As Colorado Faces Regional Shortages, Cannabis CEO Says Marijuana Will Eventually Be Traded like Any Other Commodity 2Health News:As Colorado Faces Regional Shortages, Cannabis CEO Says Marijuana Will Eventually Be Traded like Any Other Commodity 3Health News:vcfo Adds Two Senior Executives to Growing Team 2Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 2Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 3
... is so much alike the code of humans, almost a ... And yet, // there are glaring differences, despite the 98% ... not a different set of genes that caused the difference, ... According to a latest theory on evolution, even small alterations ...
... many are not aware of the Medicare part D program’s guidelines. ... Roxbury Presbyterian Church was a great relief for them. ... the bus, which has been traversing New England cities and towns ... , The deadline to sign up for new prescription drug coverage ...
... Women with disproportionate or uneven breasts have a greater likelihood ... record any alterations or changes in the breast, the study ... conducted a study where mammograms of 252 women who developed ... healthy women. It was observed that, though breast cancer ...
... psychiatrist Dr Charles Reynolds at the University of Pittsburgh which ... , The study’s main aim was to analyze the ... people. It is one of the longest studies ever ... antidepressants for longer periods, perhaps even for life, in patients ...
... nominated to run the U.S. Food and Drug Administration, ... pressure while scientific decisions were being made//. He further ... medical endeavors, the appropriateness should also be taken into ... the FDA and Director of National Cancer Institute, would ...
... years old and two adults were placed under quarantine in ... part of Maharashtra. ,Tina Nanavade from Rawer taluka, ... was admitted to Nhavi Hospital on Sunday afternoon. Tami flu ... a possible bird-flu. ,Sarla More from Jamner, a ...
Cached Medicine News:Health News:Drugs Are Effective In Treating Depression and Preventing Recurrence 2Health News:FDA Nominee Says That He Is Not Influenced By Politics 2
... volume laboratories, as well as specialty labs, ... simplicity and flexibility needed to respond to ... Elecsys 1010 system enables operators to handle ... testing without sacrificing ease of operation or ...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t...
... System provides high-performance detection technologies to ... and therapeutic drugs. It also delivers ... that allow the laboratory to streamline ... This high-productivity design enables numerous functions ...
The Embla 384 cell washer is a top-loading, robotic-compatible microplate washer for high throughput screening. It is designed specifically for cell-based assays, which require a gentler wash, but ca...
Medicine Products: